ELEKTA AB/ADR (OTCMKTS:EKTAY) – Analysts at Jefferies Financial Group issued their FY2019 earnings per share estimates for shares of ELEKTA AB/ADR in a research note issued to investors on Tuesday, December 4th. Jefferies Financial Group analyst K. Lee expects that the company will post earnings per share of $0.39 for the year. Jefferies Financial Group also issued estimates for ELEKTA AB/ADR’s FY2020 earnings at $0.45 EPS, FY2021 earnings at $0.51 EPS and FY2022 earnings at $0.57 EPS.

EKTAY has been the subject of several other reports. UBS Group upgraded shares of ELEKTA AB/ADR from a “neutral” rating to a “buy” rating in a research report on Wednesday, November 28th. Zacks Investment Research cut shares of ELEKTA AB/ADR from a “buy” rating to a “hold” rating in a research report on Tuesday, August 14th.

ELEKTA AB/ADR stock opened at $12.61 on Thursday. ELEKTA AB/ADR has a 12-month low of $7.85 and a 12-month high of $14.61. The stock has a market cap of $4.41 billion, a P/E ratio of 36.03, a PEG ratio of 2.56 and a beta of 0.43. The company has a quick ratio of 0.89, a current ratio of 1.14 and a debt-to-equity ratio of 0.63.


Elekta AB (publ) provides equipment and software for cancer and brain disorders worldwide. The company offers radiotherapy systems under the Versa HD, Precise Treatment System, and Elekta Compact names; Elekta Infinity, an image-guided radiation therapy (IGRT) system; and Elekta Synergy, a digital accelerator for advanced IGRT.

Featured Story: Bear Market – How and Why They Occur

Receive News & Ratings for ELEKTA AB/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ELEKTA AB/ADR and related companies with MarketBeat.com's FREE daily email newsletter.